Altimmune (NASDAQ:ALT) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered shares of Altimmune (NASDAQ:ALT - Free Report) from a hold rating to a sell rating in a research note published on Saturday morning.

Other research analysts have also issued research reports about the stock. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.20.

Altimmune Price Performance

Shares of NASDAQ ALT traded down $0.23 during mid-day trading on Friday, reaching $6.92. 4,326,088 shares of the company traded hands, compared to its average volume of 2,885,370. Altimmune has a fifty-two week low of $3.55 and a fifty-two week high of $11.16. The firm has a market cap of $561.26 million, a PE ratio of -4.46 and a beta of 0.58. The stock has a fifty day simple moving average of $5.35 and a 200-day simple moving average of $6.29.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. During the same quarter last year, the business earned ($0.34) earnings per share. As a group, analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Trading of Altimmune

A number of large investors have recently added to or reduced their stakes in ALT. Ameriprise Financial Inc. boosted its holdings in Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after buying an additional 1,378,854 shares in the last quarter. RFG Advisory LLC acquired a new position in Altimmune in the 1st quarter worth approximately $1,622,000. Nuveen LLC acquired a new position in Altimmune in the 1st quarter worth approximately $1,304,000. Invesco Ltd. boosted its stake in Altimmune by 679.2% in the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after purchasing an additional 215,375 shares during the period. Finally, Millennium Management LLC boosted its stake in Altimmune by 139.8% in the 4th quarter. Millennium Management LLC now owns 345,637 shares of the company's stock worth $2,492,000 after purchasing an additional 201,484 shares during the period. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.